UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

Abdul-Jawad, S; Baù, L; Alaguthurai, T; Del Molino Del Barrio, I; Laing, AG; Hayday, TS; Monin, L; ... Irshad, S; + view all (2021) Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell 10.1016/j.ccell.2021.01.001. (In press). Green open access

[img]
Preview
Text
Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients.pdf - Published version

Download (3MB) | Preview

Abstract

Given the immune system’s importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients’ immunophenotypes resemble those of nonvirus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.

Type: Article
Title: Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ccell.2021.01.001
Publisher version: https://doi.org/10.1016/j.ccell.2021.01.001
Language: English
Additional information: This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: COVID-19, SARS-CoV-2, antibodies, cancer, hemato-oncological, immune, seroconversion, vaccine, virus shedding
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10120638
Downloads since deposit
10Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item